The efficacy and safety of prokinetic agents in critically ill patients ...
2016年8月15日 · Study selection. Studies were eligible if: (1) the study design was a parallel-group randomized controlled trial (RCT); (2) the population included adult critically ill patients admitted to the ICU who received enteral nutrition; (3) the intervention group received a prokinetic agent, either domperidone, metoclopramide, or erythromycin, regardless of the dose, frequency, and duration; (4) the ...
Prokinetic agents in critical care | Critical Care | Full Text
2003年1月10日 · Prokinetic agents have a valuable role to play in this situation. A recent review by Booth and coworkers with an accompanying editorial in Critical Care Medicine systematically reviewed the evidence for the use of gastrointestinal promotility drugs in critical care. The context of the review was that promotility agents may improve tolerance to ...
Should we stop prescribing metoclopramide as a prokinetic drug …
2014年9月23日 · Regulatory agencies in North America and Europe recently re-evaluated the safety of metoclopramide. This re-evaluation resulted in recommendations and restrictions in order to minimise the risk of neurological and other adverse reactions associated with the use of metoclopramide. In the ICU, off-label prescription of metoclopramide is common. We have reviewed the evidence for safety ...
Erythromycin for prokinesis: imprudent prescribing?
2005年12月19日 · Prokinetic agents are routinely used in patients with inappropriate gastrointestinal motility. The use of erythromycin at sub-therapeutic doses as a prokinetic agent is a cause of concern for the following reasons: it can increase the emergence and spread of antibiotic resistance and the likelihood of Clostridium difficile disease. The use of ...
Metoclopramide or domperidone improves post-pyloric …
2015年12月1日 · Introduction The use of prokinetic agents on post-pyloric placement of spiral nasojejunal tubes is controversial. The aim of the present study was to examine if metoclopramide or domperidone can increase the success rate of post-pyloric placement of spiral nasojejunal tubes. Methods A multicenter, open-label, randomized, controlled trial was conducted in seven hospitals in China between April ...
Do we need new prokinetics to reduce enteral feeding intolerance …
2016年9月24日 · Gastrointestinal feeding intolerance and critical illness-associated gastric motility dysfunction are common. Although recent guidelines recommend not interrupting gastric feeding when gastric residual volume (GRV) is lower than 500 mL or to completely abandon measurement of GRV, it may seem that the relevance of prokinetics is reduced.In patients at risk for aspiration and in multimodal ...
Benefit of prokinetics during enteral nutrition: still searching for a ...
2016年10月26日 · This is in accordance with a 40 % (single prokinetic) to 49 % (double prokinetic therapy) incidence of diarrhoea that was reported in patients fed enterally , suggesting the presence of digestive malabsorption aggravated by prokinetics in the critically ill. For intensive care unit (ICU) practitioners, “enteral feeding tolerance” is often ...
prokinetic agents use in critically ill adults. Methods Study selection Studies were eligible if: (1) the study design was a parallel-group randomized controlled trial (RCT); (2) the population included adult critically ill patients admitted to the ICU who received enteral nutrition; (3) the inter-vention group received a prokinetic agent ...
Characterization of esophageal motor activity, gastroesophageal …
2021年2月8日 · Therefore, we aimed to characterize the key features of esophageal motility functions using high-resolution impedance manometry (HRIM) and to evaluate an objective link between esophageal motor patterns, gastric emptying, and gastroesophageal reflux. We also studied the prokinetic effects of metoclopramide.
Effect of erythromycin on mortality and the host response in …
2022年5月24日 · Beyond antibiotic and prokinetic effects, macrolides can profoundly modulate the immune response in a variety of ways. Their immunomodulatory efficacy is well established when used chronically for respiratory diseases such as diffuse panbronchiolitis, chronic obstructive pulmonary disease and cystic fibrosis [ 8 ].